{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:37:22Z","timestamp":1792737442869,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-026-02077-0","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:02:28Z","timestamp":1787371348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-Titer Anti-GAD Cerebellar Ataxia: Evidence That Diagnosis Should Extend Beyond Serum Antibody Levels \u2013 A Case Report and Systematic Review"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1525-449X","authenticated-orcid":false,"given":"Iogo Souza","family":"Rios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo Maciel","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"10","key":"2077_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103701","volume":"21","author":"M Dade","year":"2020","unstructured":"Dade M, Berzero G, Izquierdo C, Giry M, Benazra M, Delattre JY, et al. Neurological syndromes associated with anti-GAD antibodies. Int J Mol Sci. 2020;21(10):3701. https:\/\/doi.org\/10.3390\/ijms21103701.","journal-title":"Int J Mol Sci"},{"key":"2077_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/B978-0-444-64189-2.00021-4","volume-title":"The cerebellum: disorders and treatment. Handbook of Clinical Neurology","author":"B Joubert","year":"2018","unstructured":"Joubert B, Rost\u00e1sy K, Honnorat J. Immune-mediated ataxias. In: Manto M, Huisman TAGM, editors. The cerebellum: disorders and treatment. Handbook of Clinical Neurology. Volume 155. Amsterdam: Elsevier; 2018. pp. 313\u201332. https:\/\/doi.org\/10.1016\/B978-0-444-64189-2.00021-4."},{"issue":"3","key":"2077_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1590\/0004-282X20170020","volume":"75","author":"HAG Teive","year":"2017","unstructured":"Teive HAG. Cerebellar ataxia associated with anti-glutamic acid decarboxylase (anti-GAD) autoantibodies: a rare and puzzling disease. Arq Neuropsiquiatr. 2017;75(3):141\u20132. https:\/\/doi.org\/10.1590\/0004-282X20170020.","journal-title":"Arq Neuropsiquiatr"},{"issue":"3","key":"2077_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12311-018-0979-5","volume":"18","author":"H Mitoma","year":"2019","unstructured":"Mitoma H, Manto M, Hampe CS. Anti-GAD antibodies and the cerebellum: where do we stand? Cerebellum. 2019;18(3):384\u201392. https:\/\/doi.org\/10.1007\/s12311-018-0979-5.","journal-title":"Cerebellum"},{"issue":"2","key":"2077_CR5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s12311-023-01550-4","volume":"23","author":"M Manto","year":"2024","unstructured":"Manto M, Hadjivassiliou M, Baizabal-Carvallo JF, Hampe CS, Honnorat J, Joubert B, Mitoma H, Mu\u00f1iz-Castrillo S, Shaikh AG, Vogrig A. Consensus Paper: Latent Autoimmune Cerebellar Ataxia (LACA). Cerebellum. 2024;23(2):838\u201355. https:\/\/doi.org\/10.1007\/s12311-023-01550-4.","journal-title":"Cerebellum"},{"key":"2077_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/NDT.S19217","volume":"7","author":"S El-Tawil","year":"2011","unstructured":"El-Tawil S, El-Metwally TH, Shalaby NM, El-Belkimy GS, El-Sayed MM. Population-based study of acquired cerebellar ataxia in Al-Kharga district, New Valley, Egypt. Neuropsychiatr Dis Treat. 2011;7:493\u2013500. https:\/\/doi.org\/10.2147\/NDT.S19217.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"2077_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12311-012-0411-5","volume":"12","author":"K Nanri","year":"2013","unstructured":"Nanri K, Niwa H, Mitoma H, Takei A, Ikeda J, Harada T, et al. Low-titer anti-GAD-antibody-positive cerebellar ataxia. Cerebellum. 2013;12(2):171\u20135. https:\/\/doi.org\/10.1007\/s12311-012-0411-5.","journal-title":"Cerebellum"},{"key":"2077_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211003486","volume":"14","author":"P Tsiortou","year":"2021","unstructured":"Tsiortou P, Alexopoulos H, Dalakas MC. GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord. 2021;14:17562864211003486. https:\/\/doi.org\/10.1177\/17562864211003486.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"2077_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/WCO.0000000000000678","volume":"32","author":"B Joubert","year":"2019","unstructured":"Joubert B, Honnorat J. Nonparaneoplastic autoimmune cerebellar ataxias. Curr Opin Neurol. 2019;32(3):484\u201392. https:\/\/doi.org\/10.1097\/WCO.0000000000000678.","journal-title":"Curr Opin Neurol"},{"key":"2077_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40673-021-00134-0","volume":"8","author":"M Hadjivassiliou","year":"2021","unstructured":"Hadjivassiliou M, et al. The neurobiology of gluten sensitivity: the role of anti-GAD antibodies. Cerebellum Ataxias. 2021;8:1\u201311. https:\/\/doi.org\/10.1186\/s40673-021-00134-0.","journal-title":"Cerebellum Ataxias"},{"issue":"1","key":"2077_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/jnnp.2007.142745","volume":"80","author":"R Virgilio","year":"2009","unstructured":"Virgilio R, Corti S, Agazzi P, Santoro D, Lanfranconi S, Candelise L, et al. Effect of steroid treatment in cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry. 2009;80(1):95\u20136. https:\/\/doi.org\/10.1136\/jnnp.2007.142745.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2077_CR12","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/j.1468-1331.2009.02839.x","volume":"17","author":"V Nociti","year":"2010","unstructured":"Nociti V, Frisullo G, Tartaglione T, Patanella AK, Iorio R, Tonali PA, Batocchi AP. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. Eur J Neurol. 2010;17(1):e5. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02839.x.","journal-title":"Eur J Neurol"},{"issue":"8","key":"2077_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.revmed.2006.04.006","volume":"27","author":"B Birand","year":"2006","unstructured":"Birand B, Cabre P, Bonnan M, Olindo S, Smadja D. A new case of cerebellar ataxia with anti-GAD antibodies treated with corticosteroids and initially seronegative. Rev Med Interne. 2006;27(8):616\u20139. https:\/\/doi.org\/10.1016\/j.revmed.2006.04.006.","journal-title":"Rev Med Interne"},{"issue":"2","key":"2077_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cen3.12381","volume":"8","author":"K Sato","year":"2017","unstructured":"Sato K, Arai N, Bannai T, Kodama S, Omori-Mitsue A, Hida A, et al. Autoimmune cerebellar ataxia with initial seronegativity and low-titer anti-glutamic acid decarboxylase antibody in the cerebrospinal fluid. Clin Exp Neuroimmunol. 2017;8(2):158\u201361. https:\/\/doi.org\/10.1111\/cen3.12381.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"4","key":"2077_CR15","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s12311-017-0851-z","volume":"16","author":"T Petrijan","year":"2017","unstructured":"Petrijan T, Menih M. Low-titre GAD antibody-associated late-onset cerebellar ataxia with a significant clinical response to intravenous immunoglobulin treatment. Cerebellum. 2017;16(4):868\u201371. https:\/\/doi.org\/10.1007\/s12311-017-0851-z.","journal-title":"Cerebellum"},{"issue":"6","key":"2077_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1590\/S0004-282X2011000700030","volume":"69","author":"JL Pedroso","year":"2011","unstructured":"Pedroso JL, Braga-Neto P, Dutra LA, Barsottini OGP. Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy. Arq Neuropsiquiatr. 2011;69(6):993. https:\/\/doi.org\/10.1590\/S0004-282X2011000700030.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"2077_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/ncn3.138","volume":"3","author":"T Takino","year":"2015","unstructured":"Takino T, Fukushima T, Yanagimura F, Makino K. Case of subacute cerebellar ataxia with anti-glutamic acid decarboxylase antibodies in cerebrospinal fluid, but not in serum. Neurol Clin Neurosci. 2015;3(1):44\u20135. https:\/\/doi.org\/10.1111\/ncn3.138.","journal-title":"Neurol Clin Neurosci"},{"issue":"3","key":"2077_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1590\/0004-282X20170011","volume":"75","author":"TS Aguiar","year":"2017","unstructured":"Aguiar TS, Fragoso A, Albuquerque CR, Teixeira PF, Souza MVL, Zajdenverg L, et al. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies. Arq Neuropsiquiatr. 2017;75(3):142\u20136. https:\/\/doi.org\/10.1590\/0004-282X20170011.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"2077_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000494423","volume":"141","author":"L Shargian-Alon","year":"2019","unstructured":"Shargian-Alon L, Raanani P, Rozovski U, Siegal T, Yust-Katz S, Yeshurun M. Immune mediated cerebellar ataxia: an unknown manifestation of graft-versus-host disease. Acta Haematol. 2019;141(1):19\u201322. https:\/\/doi.org\/10.1159\/000494423.","journal-title":"Acta Haematol"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-026-02077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-026-02077-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-026-02077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:37:31Z","timestamp":1792733851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-026-02077-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1007\/s12311-026-02077-0","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"23 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by the local Research Ethics Committee, in accordance with national regulations and the Declaration of Helsinki. Written informed consent was obtained from the patient for participation in this study.","order":1,"name":"Ethics","label":"Human Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"131"}}